Trials / Terminated
TerminatedNCT03467958
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 854 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozanimod | Specified dose on specified days |
Timeline
- Start date
- 2018-08-24
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
- First posted
- 2018-03-16
- Last updated
- 2025-09-17
- Results posted
- 2025-09-17
Locations
766 sites across 49 countries: United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Saudi Arabia, Senegal, Serbia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03467958. Inclusion in this directory is not an endorsement.